Notably, while Wegovy was first approved in June 2021, high out-of-pocket costs, sparse insurance coverage, and factory-related shortages likely limited how many eligible people could obtain these medications early on, which might help explain the delay in declining surgery rates
Although I do feel like I'm withering away." Anonymous, 45, female 16
Severe Gastrointestinal Disease: Zepbound (tirzepatide) is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe
3) How to calculate your caloric needs
Mitrovi A, Brki P, Jovanovi T